Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Dig Dis Sci. 2010 Jul;55(7):1839-51. doi: 10.1007/s10620-009-0944-8.
Diabetes mellitus increases the risk of incident colorectal cancer, but it is less clear if pre-existing diabetes mellitus influences mortality outcomes, recurrence risk, and/or treatment-related complications in persons with colorectal cancer.
We performed a systematic review and meta-analysis comparing colorectal cancer mortality outcomes, cancer recurrence, and treatment-related complications in persons with and without diabetes mellitus. We searched MEDLINE and EMBASE through October 1, 2008, including hand-searching references of qualifying articles. We included studies in English that evaluated diabetes mellitus and cancer treatment outcomes, prognosis, and/or mortality. The initial search identified 8,208 titles, of which 15 articles met inclusion criteria. Each article was abstracted by one author using a standardized form and re-reviewed by another author for accuracy. Authors graded quality based on pre-determined criteria.
We found significantly increased short-term perioperative mortality in persons with diabetes mellitus. In the meta-analysis of long-term mortality, persons with diabetes mellitus had a 32% increase in all-cause mortality compared to those without diabetes mellitus (95% CI: 1.24, 1.41). Although data on other outcomes are limited, available studies suggest that pre-existing diabetes mellitus predicts increased risk of some post-operative complications as well as 5-year cancer recurrence. In contrast, there is little evidence that diabetes confers increased risk for long-term cancer-specific mortality.
Patients with colorectal cancer and pre-existing diabetes mellitus have an increased risk of short- and long-term mortality. Future research should determine whether improvements in prevention and treatment of diabetes mellitus will improve outcomes for colorectal cancer patients.
糖尿病会增加结直肠癌的发病风险,但目前尚不清楚糖尿病是否会影响结直肠癌患者的死亡率、复发风险和/或治疗相关并发症。
我们进行了一项系统评价和荟萃分析,比较了合并和不合并糖尿病的结直肠癌患者的死亡率结局、癌症复发以及与治疗相关的并发症。我们通过 MEDLINE 和 EMBASE 进行了检索,检索时间截至 2008 年 10 月 1 日,同时还对纳入研究的参考文献进行了手工检索。我们纳入了评估糖尿病与癌症治疗结局、预后和/或死亡率的英文研究。最初的检索共得到 8208 个标题,其中 15 篇文章符合纳入标准。每位作者均使用标准化表格对每篇文章进行摘要,并由另一位作者进行准确性复查。作者根据预先确定的标准对质量进行分级。
我们发现合并糖尿病的患者在短期围手术期死亡率显著升高。在长期死亡率的荟萃分析中,与不合并糖尿病的患者相比,合并糖尿病的患者全因死亡率增加了 32%(95%CI:1.24,1.41)。尽管其他结局的数据有限,但现有研究表明,糖尿病会增加某些术后并发症和 5 年癌症复发的风险。相比之下,糖尿病是否会增加长期癌症特异性死亡率的风险,目前尚无明确证据。
患有结直肠癌且合并糖尿病的患者存在短期和长期死亡风险增加的情况。未来的研究应明确预防和治疗糖尿病是否能改善结直肠癌患者的结局。